Mod­er­na eyes PhI­II start for com­bo mR­NA jab tar­get­ing Covid and flu af­ter PhI/II suc­cess

Mod­er­na’s com­bi­na­tion vac­cine can­di­date for Covid-19 and in­fluen­za, mR­NA-1083, has shown ear­ly po­ten­tial in a mid-stage tri­al, spark­ing plans for reg­is­tra­tional de­vel­op­ment lat­er this year.

The on­go­ing Phase I/II tri­al is com­par­ing mR­NA-1083 to a stan­dard dose of Flu­ar­ix or high-dose Flu­zone, de­pend­ing on pa­tient age, and Mod­er­na’s own Spike­vax boost­er for Covid-19.

The com­bi­na­tion vac­cine is one of 15 prod­ucts the US biotech aims to bring to mar­ket over the next five years. Mod­er­na’s am­bi­tious plans al­so in­clude ad­vanc­ing up to 50 mR­NA pro­grams in­to the clin­ic with­in the same time­frame. But its jab can­di­date for in­fluen­za on­ly, mR­NA-1010, has yield­ed mixed da­ta in the past, al­though it has since suc­ceed­ed at Phase III.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER